Evidence method
Level · gp.fundamentals.capex_revenue_ratio
1.85% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Jun 30, 2025
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001178670-25-000090General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
19.87% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
17.26% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
9.27% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
81.64% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-2.09% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
41.83% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
14.43% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 1.51%
- Current
- 1.85%
- Delta
- 0.34%
- Previous
- -19.91%
- Current
- 19.87%
- Delta
- 39.78%
- Previous
- 20.20%
- Current
- 17.26%
- Delta
- -2.94%
- Previous
- 11.04%
- Current
- 9.27%
- Delta
- -1.77%
- Previous
- 88.19%
- Current
- 81.64%
- Delta
- -6.55%
- Previous
- 3.04%
- Current
- -2.09%
- Delta
- -5.14%
- Previous
- 44.62%
- Current
- 41.83%
- Delta
- -2.79%
- Previous
- 9.54%
- Current
- 14.43%
- Delta
- 4.89%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_INCREASED →Transitioned To · ALNY CASH_GENERATION_INCREASED →Transitioned To · ALNY GROWTH_DECREASED →Transitioned To · ALNY INVENTORY_PRESSURE_DECREASED →Transitioned To · ALNY MARGIN_DECREASED →Transitioned To · ALNY PROFITABILITY_DECREASED →Transitioned To · ALNY R_AND_D_INTENSITY_DECREASED →Transitioned To · ALNY SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.